We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
RNS Number : 1101W
Diurnal Group PLC
09 November 2017
9 November 2017
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealing and Issue of Equity
On 8 November 2017, Diurnal issued a total of 109,296 new ordinary shares of 5 pence in the Company ("Shares") under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 69,565 new Shares to persons discharging managerial responsibilities ("PDMR"):
PDMR Total number of Shares Nature of issuance issued ---------------- ----------------------- -------------------- Martin Whitaker 69,565 Vesting of Deferred Bonus Award
The Shares issued were awarded on a deferred basis on 8 November 2016, as previously notified on 9 November 2016. Upon receipt of these shares, Martin Whitaker subsequently sold 33,650 ordinary shares to settle payment of all tax and NI requirements in relation to the award as set out in the notification below.
Issue of equity
Application has been made to AIM for the admission of the 109,296 new Shares, which is anticipated to occur at 8.00am on 15 November 2017. The Company has also made application for admission to AIM at the same time of the following shares that have previously been duly issued and allotted but not admitted to trading: 110,000 new Shares issued on 12 April 2017 in respect of the exercise of options by a former employee at an exercise price of 43.77p per new Share; 10,791 new Shares issued on 7 September 2017 in respect of the vesting of shares to Mr John Goddard, NED of the Company, at a price of 5p per new Share (as announced on 7 September 2017); 100,000 new Shares issued on 21 September 2017 in respect of the exercise of options by a former director at an exercise price of 0.2p per new Share; and 29,000 new Shares issued on 21 September 2017 in respect of the exercise of options by an employee at an exercise price of 43.77p per new Share.
Following admission of the new Shares, the Company's total issued share capital will be 52,569,846 Ordinary Shares. Therefore, the total number of voting rights in the Company is 52,569,846. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations
1 Details of the person discharging managerial responsibilities / person closely associated ---- ------------------------------------------------------------------- a) Name Martin Whitaker ---- ------------------------------ ----------------------------------- 2 Reason for the notification ---- ------------------------------------------------------------------- a) Position/status Chief Executive Officer ---- ------------------------------ ----------------------------------- b) Initial notification Initial notification /Amendment ---- ------------------------------ ----------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ------------------------------------------------------------------- a) Name Diurnal Group plc ---- ------------------------------ ----------------------------------- b) LEI 213800I2HNUNZN1LDH29 ---- ------------------------------ ----------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ------------------------------------------------------------------- a) Description of Ordinary Shares of 5 pence the financial each in Diurnal Group plc instrument, type of instrument ---- Identification GB00BDB6Q760 code b) Nature of the Vesting of awards under the transaction Diurnal Group plc Long Term Incentive Plan as follows: EMI deferred bonus award over 9,730 ordinary shares. Non-EMI deferred bonus award over 59,835 ordinary shares. ---- ------------------------------ ----------------------------------- c) Price(s) and volume(s) ---- --------------- --------------- Price(s) Volume(s) ---- --------------- --------------- 120p 9,730 --------------- --------------- 120p 59,835 --------------- --------------- d) Aggregated information ---- - Aggregated volume 69,565 ordinary shares - Price GBP83,478.00 e) Date of the transaction 8 November 2017 ---- ------------------------------ ----------------------------------- f) Place of the transaction Off market ---- ------------------------------ ----------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated ---- ---------------------------------------------------------------- a) Name Martin Whitaker ---- ----------------------------- --------------------------------- 2 Reason for the notification ---- ---------------------------------------------------------------- a) Position/status Chief Executive Officer ---- ----------------------------- --------------------------------- b) Initial notification Initial notification /Amendment ---- ----------------------------- --------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ---------------------------------------------------------------- a) Name Diurnal Group plc ---- ----------------------------- --------------------------------- b) LEI 213800I2HNUNZN1LDH29 ---- ----------------------------- --------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------- a) Description of Ordinary Shares of 5 pence the financial each in Diurnal Group plc instrument, type of instrument ---- Identification GB00BDB6Q760 code b) Nature of the Sale of 33,650 shares transaction ---- ----------------------------- --------------------------------- c) Price(s) and volume(s) ---- ---------------- ------------ Price(s) Volume(s) ---- ---------------- ------------ 134.7p per share 33,650 --------------------------------------------------- ------------ d) Aggregated information ---- - Aggregated volume 33,650 ordinary shares - Price GBP45,326.55 e) Date of the transaction 8 November 2017 ---- ----------------------------- --------------------------------- f) Place of the transaction XLON ---- ----------------------------- --------------------------------- For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Numis Securities Ltd (Nominated +44 (0)20 7260 Adviser) 1000 Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield Corporate Broking: James Black Panmure Gordon (UK) Limited (Joint +44 (0) 20 7886 Broker) 2500 Corporate Finance: Freddy Crossley / Duncan Monteith Corporate Broking: Tom Salvesen +44 (0)20 3727 FTI Consulting 1000 Simon Conway Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFSIFAUFWSEFF
(END) Dow Jones Newswires
November 09, 2017 13:19 ET (18:19 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions